219 related articles for article (PubMed ID: 27428551)
1. The Mexican Acromegaly Registry: Clinical and Biochemical Characteristics at Diagnosis and Therapeutic Outcomes.
Portocarrero-Ortiz LA; Vergara-Lopez A; Vidrio-Velazquez M; Uribe-Diaz AM; García-Dominguez A; Reza-Albarrán AA; Cuevas-Ramos D; Melgar V; Talavera J; Rivera-Hernandez AJ; Valencia-Méndez CV; Mercado M;
J Clin Endocrinol Metab; 2016 Nov; 101(11):3997-4004. PubMed ID: 27428551
[TBL] [Abstract][Full Text] [Related]
2. Surgical and Pharmacological Outcomes in Acromegaly: Real-Life Data From the Mexican Acromegaly Registry.
Mercado M; Abreu C; Vergara-López A; González-Virla B; Espinosa-de-Los-Monteros AL; Sosa-Eroza E; Cadena-Obando D; Cuevas-Ramos D; Portocarrero-Ortiz LA; Pérez-Reyes SP; Mercado-Cherem A; Ibarra-Salce R; Talavera JO
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32944780
[TBL] [Abstract][Full Text] [Related]
3. Acromegaly.
Scacchi M; Cavagnini F
Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
[TBL] [Abstract][Full Text] [Related]
4. Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study.
Esposito D; Ragnarsson O; Granfeldt D; Marlow T; Johannsson G; Olsson DS
Eur J Endocrinol; 2018 May; 178(5):459-469. PubMed ID: 29483205
[TBL] [Abstract][Full Text] [Related]
5. [Current diagnosis and treatment of acromegaly].
Melgar V; Espinosa E; Cuenca D; Valle V; Mercado M
Rev Med Inst Mex Seguro Soc; 2015; 53(1):74-83. PubMed ID: 25680646
[TBL] [Abstract][Full Text] [Related]
6. [Epidemiology of acromegaly in Spain].
Sesmilo G
Endocrinol Nutr; 2013 Oct; 60(8):470-4. PubMed ID: 23246411
[TBL] [Abstract][Full Text] [Related]
7. Cardiac risk in patients with treatment naïve, first-line medically controlled and first-line surgically cured acromegaly in comparison to matched data from the general population.
Berg C; Petersenn S; Walensi M; Möhlenkamp S; Bauer M; Lehmann N; Roggenbuck U; Moebus S; Broecker-Preuss M; Sandalcioglu IE; Stolke D; Sure U; Joeckel KH; Erbel R; Führer D; Mann K;
Exp Clin Endocrinol Diabetes; 2013 Feb; 121(2):125-32. PubMed ID: 23338744
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of medical treatment in patients with acromegaly in clinical practice.
Lee SY; Kim JH; Lee JH; Kim YH; Cha HJ; Kim SW; Paek SH; Shin CS
Endocr J; 2018 Jan; 65(1):33-41. PubMed ID: 28931779
[TBL] [Abstract][Full Text] [Related]
9. Fractures in pituitary adenoma patients from the Dutch National Registry of Growth Hormone Treatment in Adults.
van Varsseveld NC; van Bunderen CC; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
Pituitary; 2016 Aug; 19(4):381-90. PubMed ID: 27048484
[TBL] [Abstract][Full Text] [Related]
10. Pituitary tumours: acromegaly.
Chanson P; Salenave S; Kamenicky P; Cazabat L; Young J
Best Pract Res Clin Endocrinol Metab; 2009 Oct; 23(5):555-74. PubMed ID: 19945023
[TBL] [Abstract][Full Text] [Related]
11. A prospective analysis of 151 cases of patients with acromegaly operated by one neurosurgeon: a follow-up of more than 23 years.
Abbassioun K; Amirjamshidi M; Mehrazin A; Khalatbary I; Keynama M; Bokai H; Abdollahi M
Surg Neurol; 2006 Jul; 66(1):26-31; discussion 31. PubMed ID: 16793431
[TBL] [Abstract][Full Text] [Related]
12. Acromegaly, a pituitary special issue.
Fleseriu M; Gadelha M
Pituitary; 2017 Feb; 20(1):2-3. PubMed ID: 28255899
[No Abstract] [Full Text] [Related]
13. Prevalence, incidence, comorbidities, and treatment patterns among Japanese patients with acromegaly: a descriptive study using a nationwide claims database.
Matsubayashi K; Kawakami K
Endocr J; 2020 Oct; 67(10):997-1006. PubMed ID: 32522909
[TBL] [Abstract][Full Text] [Related]
14. Paradoxical GH Increase During OGTT Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly.
Scaroni C; Albiger N; Daniele A; Dassie F; Romualdi C; Vazza G; Regazzo D; Ferraù F; Barresi V; Maffeis V; Gardiman MP; Cannavò S; Maffei P; Ceccato F; Losa M; Occhi G
J Clin Endocrinol Metab; 2019 Mar; 104(3):856-862. PubMed ID: 30285115
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
Suda K; Inoshita N; Iguchi G; Fukuoka H; Takahashi M; Nishizawa H; Yamamoto M; Yamada S; Takahashi Y
Endocr J; 2013; 60(4):507-15. PubMed ID: 23291436
[TBL] [Abstract][Full Text] [Related]
16. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic trends and outcome of acromegaly: a single center experience over a 40-year period.
Karapanou O; Tzanela M; Christoforaki M; Papastathopoulou L; Moutsatsou P; Botoula E; Tsagarakis S
Hormones (Athens); 2016 Jul; 15(3):368-376. PubMed ID: 27394702
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of pituitary adenomas].
Mezosi E; Nemes O
Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
[TBL] [Abstract][Full Text] [Related]
19. Nationwide survey of acromegaly in South Korea.
Kwon O; Song YD; Kim SY; Lee EJ;
Clin Endocrinol (Oxf); 2013 Apr; 78(4):577-85. PubMed ID: 22909047
[TBL] [Abstract][Full Text] [Related]
20. A registry of acromegaly patients and one year following up in Taiwan.
Tseng FY; Huang TS; Lin JD; Chen ST; Wang PW; Chen JF; Huey-Herng Sheu W; Chang TC;
J Formos Med Assoc; 2019 Oct; 118(10):1430-1437. PubMed ID: 30612883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
